These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27357340)

  • 1. Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.
    Deruaz M; Moldt B; Le KM; Power KA; Vrbanac VD; Tanno S; Ghebremichael MS; Allen TM; Tager AM; Burton DR; Luster AD
    J Infect Dis; 2016 Aug; 214(4):612-6. PubMed ID: 27357340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.
    Moldt B; Le KM; Carnathan DG; Whitney JB; Schultz N; Lewis MG; Borducchi EN; Smith KM; Mackel JJ; Sweat SL; Hodges AP; Godzik A; Parren PW; Silvestri G; Barouch DH; Burton DR
    AIDS; 2016 Jun; 30(10):1543-51. PubMed ID: 27243773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.
    Veselinovic M; Neff CP; Mulder LR; Akkina R
    Virology; 2012 Oct; 432(2):505-10. PubMed ID: 22832125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
    Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.
    Safrit JT; Fung MS; Andrews CA; Braun DG; Sun WN; Chang TW; Koup RA
    AIDS; 1993 Jan; 7(1):15-21. PubMed ID: 7680205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antibody treatment controls HIV infection in phase 1 trial.
    Harper KN
    AIDS; 2019 Mar; 33(3):N3-N4. PubMed ID: 30585848
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.
    Stoddart CA; Galkina SA; Joshi P; Kosikova G; Long BR; Maidji E; Moreno ME; Rivera JM; Sanford UR; Sloan B; Cieplak W; Wrin T; Chan-Hui PY
    Virology; 2014 Aug; 462-463():115-25. PubMed ID: 24971704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection.
    Parsons MS; Le Grand R; Kent SJ
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29912167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in HIV-1 antibody research using humanized mice.
    Gruell H; Klein F
    Curr Opin HIV AIDS; 2017 May; 12(3):285-293. PubMed ID: 28422792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of HIV infection by passive immunization with HIV immunoglobulin.
    Prince AM; Reesink H; Pascual D; Horowitz B; Hewlett I; Murthy KK; Cobb KE; Eichberg JW
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):971-3. PubMed ID: 1812946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Based Preventive and Therapeutic Strategies Against HIV.
    Fabra-Garcia A; Beltran C; Sanchez-Merino V; Yuste E
    Curr HIV Res; 2016; 14(3):260-9. PubMed ID: 26957200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vector-Mediated In Vivo Antibody Expression.
    Schnepp BC; Johnson PR
    Microbiol Spectr; 2014 Aug; 2(4):AID-0016-2014. PubMed ID: 26104192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.
    Nimmerjahn F
    Eur J Immunol; 2015 Aug; 45(8):2183-90. PubMed ID: 26140474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
    Gauduin MC; Safrit JT; Weir R; Fung MS; Koup RA
    J Infect Dis; 1995 May; 171(5):1203-9. PubMed ID: 7751695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2015 Jul; 33(31):3605-8. PubMed ID: 25769208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.